J3489
J3489 – Injection, zoledronic acid, 1 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 41 NDCs crosswalked per 1 MG $3.361/unit ASP+6%
📋 J3489 summary
J3489 is a HCPCS Level II J-code used to bill zoledronic acid, 1 mg, billed per 1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J3489: Reclast*, Zoledronic Acid, Reclast
Code J3489
Billing unit 1 MG Payment limit $3.361/unit NDC-Crosswalk 41
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ3489
DescriptorInjection, zoledronic acid, 1 mg
Billing unit1 MG
Payment limit / unit$3.361
Est. ASP / unit$3.171 est.
Mapped NDCs41
Data periodQ3 2026
Last updated2026-09-20
💊 About Zoledronic Acid Injection DRUG GUIDE
Zoledronic acid injection is a bisphosphonate given through a vein.
The label describes two groups of uses, and not every product is used for every condition.One group is bone conditions: osteoporosis in postmenopausal women (treatment and prevention), osteoporosis in men, glucocorticoid-induced osteoporosis (bone loss from steroid medicines), and Paget’s disease of bone.
The other group is cancer-related: hypercalcemia of malignancy (high blood calcium caused by cancer), multiple myeloma, and bone metastases from solid tumors.
Your prescriber chooses the specific product for your condition.
Clinical overview from our editorial drug guide for Zoledronic Acid Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$3.361
Est. ASP / unit
$3.171 est.
Est. after 2% sequester
$3.294
HCPCS dosage
1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, zoledronic acid, 1 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeN — No maintenance this year
Effective date2018-01-01
Date added2014-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J3489 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J3489 LEAST EXPENSIVE FIRST
41 NDCs map to J3489. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($3.361/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 55111-0688-52 | Zoledronic Acid 5 mg/100mL INJECTION, SOLUTION | Dr.Reddy's | 100 mL in 1 BOTTLE, GLASS (55111-688-52) | 5 mg/100mL | 5 | $16.81 | $0.475 | ● Active | CMS ASP |
| 63323-0966-00 | Zoledronic Acid 5 mg/100mL INJECTION, SOLUTION | Fresenius | 1 VIAL, GLASS in 1 CARTON (63323-966-00)... | 5 mg/100mL | 5 | $16.81 | $0.475 | ● Active | CMS + PDAC |
| 67457-0619-10 | Zoledronic Acid 5 mg/100mL INJECTION, SOLUTION | Mylan | 1 VIAL in 1 CARTON (67457-619-10) / 100 m... | 5 mg/100mL | 5 | $16.81 | $0.475 | ● Active | CMS + PDAC |
| 71288-0806-51 | Zoledronic Acid 5 mg/100mL INJECTION, SOLUTION | Meitheal | 1 BOTTLE, GLASS in 1 CARTON (71288-806-51)... | 5 mg/100mL | 5 | $16.81 | $0.475 | ● Active | CMS + PDAC |
| 00078-0435-61 | Reclast | Sandoz | — | — | 5 | $16.81 | — | — | CMS ASP |
| 16714-0815-01 | Zoledronic Acid | Northstar | — | — | 4 | $13.44 | — | — | CMS ASP |
| 16729-0242-31 | Zoledronic acid 4 mg/5mL INJECTION | Accord | 1 VIAL in 1 CARTON (16729-242-31) / 5 mL... | 4 mg/5mL | 4 | $13.44 | — | ● Active | CMS + PDAC |
| 23155-0170-31 | Zoledronic acid 4 mg/5mL INJECTION, SOLUTION, CONCENTRATE | Heritage | 1 VIAL, GLASS in 1 CARTON (23155-170-31)... | 4 mg/5mL | 4 | $13.44 | — | ● Active | CMS ASP |
| 25021-0801-66 | Zoledronic Acid | Sagent | — | — | 4 | $13.44 | — | — | CMS ASP |
| 25021-0826-67 | zoledronic acid .04 mg/mL INJECTION, SOLUTION | Sagent | 1 BAG in 1 CARTON (25021-826-67) / 100 mL... | .04 mg/mL | 4 | $13.44 | — | ● Active | CMS ASP |
| 25021-0826-82 | zoledronic acid .04 mg/mL INJECTION, SOLUTION | Sagent | 1 BAG in 1 CARTON (25021-826-82) / 100 mL... | .04 mg/mL | 4 | $13.44 | — | ● Active | CMS ASP |
| 25021-0830-82 | zoledronic acid .05 mg/mL INJECTION, SOLUTION | Sagent | 1 BAG in 1 CARTON (25021-830-82) / 100 mL... | .05 mg/mL | 5 | $16.81 | — | ● Active | CMS ASP |
| 25021-0830-87 | zoledronic acid .05 mg/mL INJECTION, SOLUTION | Sagent | 5 BAG in 1 CARTON (25021-830-87) / 100 mL... | .05 mg/mL | 25 | $84.03 | — | ● Active | CMS + PDAC |
| 43598-0233-11 | Zoledronic Acid 4 mg/5mL INJECTION, SOLUTION, CONCENTRATE | Dr. | 1 VIAL, GLASS in 1 CARTON (43598-233-11)... | 4 mg/5mL | 4 | $13.44 | — | ● Active | CMS + PDAC |
| 55111-0685-07 | Zoledronic Acid 4 mg/5mL INJECTION, SOLUTION, CONCENTRATE | Dr. | 1 VIAL, GLASS in 1 CARTON (55111-685-07)... | 4 mg/5mL | 4 | $13.44 | — | ● Active | CMS ASP |
| 63323-0961-98 | Zoledronic Acid 4 mg/5mL INJECTION | Fresenius | 1 VIAL in 1 CARTON (63323-961-98) / 5 mL... | 4 mg/5mL | 4 | $13.44 | — | ● Active | CMS ASP |
| 66758-0155-46 | Reclast zoledronic acid 5 mg/100mL INJECTION, SOLUTION | Sandoz | 100 mL in 1 BOTTLE (66758-155-46) | 5 mg/100mL | 5 | $16.81 | — | ● Active | CMS + PDAC |
| 67457-0390-54 | Zoledronic acid 4 mg/5mL INJECTION, SOLUTION, CONCENTRATE | Mylan | 1 VIAL in 1 CARTON (67457-390-54) / 5 mL... | 4 mg/5mL | 4 | $13.44 | — | ● Active | CMS ASP |
| 67457-0794-10 | Zoledronic Acid 5 mg/100mL INJECTION, SOLUTION | Mylan | 1 BAG in 1 POUCH (67457-794-10) / 100 mL... | 5 mg/100mL | 5 | $16.81 | — | ● Active | CMS + PDAC |
| 68001-0437-25 | Zoledronic acid 4 mg/5mL INJECTION | BluePoint | 1 VIAL in 1 CARTON (68001-437-25) / 5 mL... | 4 mg/5mL | 4 | $13.44 | — | ● Active | CMS + PDAC |
| 68001-0610-25 | Zoledronic acid 4 mg/5mL INJECTION, SOLUTION, CONCENTRATE | BluePoint | 1 VIAL, GLASS in 1 CARTON (68001-610-25)... | 4 mg/5mL | 4 | $13.44 | — | ● Active | CMS + PDAC |
| 68001-0611-33 | Zoledronic acid 5 mg/100mL INJECTION | BluePoint | 1 BAG in 1 CARTON (68001-611-33) / 100 mL... | 5 mg/100mL | 5 | $16.81 | — | ● Active | CMS + PDAC |
| 70860-0210-51 | Zoledronic Acid | Athenex | — | — | 4 | $13.44 | — | — | CMS + PDAC |
| 70860-0802-82 | Zoledronic Acid | Athenex | — | — | 5 | $16.81 | — | — | CMS + PDAC |
| 72266-0152-01 | Zoledronic acid 5 mg/100mL INJECTION | FOSUN | 1 BAG in 1 CARTON (72266-152-01) / 100 mL... | 5 mg/100mL | 5 | $16.81 | — | ● Active | CMS + PDAC |
| 72603-0198-01 | Zoledronic acid 4 mg/5mL INJECTION, SOLUTION, CONCENTRATE | NORTHSTAR | 1 VIAL, GLASS in 1 CARTON (72603-198-01)... | 4 mg/5mL | 4 | $13.44 | — | ● Active | CMS + PDAC |
| 54288-0183-01 | Zoledronic Acid 4 mg/5mL INJECTION, SOLUTION, CONCENTRATE | BPI | 1 VIAL, GLASS in 1 CARTON (54288-183-01)... | 4 mg/5mL | 0.8 | $2.69 | — | ● Active | PDAC |
| 25021-0826-87 | zoledronic acid .04 mg/mL INJECTION, SOLUTION | Sagent | 5 BAG in 1 CARTON (25021-826-87) / 100 mL... | .04 mg/mL | 0.04 | $0.13 | — | ● Active | PDAC |
| 69367-0190-50 | Zoledronic Acid 4 mg/5mL INJECTION | Westminster | 1 VIAL in 1 CARTON (69367-190-50) / 5 mL... | 4 mg/5mL | 0.8 | $2.69 | — | ● Active | PDAC |
| 54288-0100-01 | Zoledronic Acid 4 mg/5mL INJECTION, SOLUTION, CONCENTRATE | BPI | 1 VIAL in 1 CARTON (54288-100-01) / 5 mL... | 4 mg/5mL | 0.8 | $2.69 | — | ● Active | PDAC |
| 55150-0266-05 | Zoledronic Acid 4 mg/5mL INJECTION, SOLUTION, CONCENTRATE | AuroMedics | 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-266... | 4 mg/5mL | 0.8 | $2.69 | — | ● Active | PDAC |
| 67457-0920-05 | ZOLEDRONIC ACID NOVAPLUS (SINGLE USE) 4 MG/5 ML | Unknown | — | — | 0.8 | $2.69 | — | — | PDAC |
| 50742-0416-05 | ZOLEDRONIC ACID (SDV) 4 MG/5 ML | Unknown | — | — | 0.8 | $2.69 | — | — | PDAC |
| 00409-4215-05 | PREMIERPRO RX ZOLEDRONIC ACID 4 MG/5 ML | Unknown | — | — | 0.8 | $2.69 | — | — | PDAC |
| 68001-0366-25 | ZOLEDRONIC ACID (SDV) 4 MG/5 ML | Unknown | — | — | 0.8 | $2.69 | — | — | PDAC |
| 51991-0065-98 | ZOLEDRONIC ACID (SINGLE-USE) 4 MG/5 ML | Unknown | — | — | 0.8 | $2.69 | — | — | PDAC |
| 51991-0064-98 | ZOLEDRONIC ACID (1X100ML,SINGLE USE) 5 MG/100 ML | Unknown | — | — | 0.05 | $0.17 | — | — | PDAC |
| 00409-4215-01 | ZOLEDRONIC ACID (SINGLE USE) 4 MG/5 ML | Unknown | — | — | 0.8 | $2.69 | — | — | PDAC |
| 00409-4229-01 | ZOLEDRONIC ACID (SINGLE USE,LATEX-FREE) 4 MG/100 ML | Unknown | — | — | 0.04 | $0.13 | — | — | PDAC |
| 00409-4228-01 | ZOLEDRONIC ACID (SINGLE USE,LATEX-FREE) 5 MG/100 ML | Unknown | — | — | 0.05 | $0.17 | — | — | PDAC |
| 60505-6110-00 | ZOLEDRONIC ACID (SDV) 4 MG/5 ML | Unknown | — | — | 0.8 | $2.69 | — | — | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$779.5K
Claims
34,241
Beneficiaries
30,769
Spend / beneficiary
$25.34
Spend / claim
$22.77
Trend by period
Where J3489 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #404 of 824
#399
FEIBA J7198
$830K
#400
CYCLOSPORINE MODIFIE... J7515
$811.9K
#401
COMPLETE SL PER SQ C... Q4270
$803.1K
#402
CYCLOPHOSPHAMIDE(J90... J9073
$799.5K
#403
XIPERE J3299
$787.6K
#404
RECLAST* J3489
$779.5K
#405
AFFINITY1 SQUARE CM*... Q4159
$769.7K
#406
IRON SUCROSE* J1756
$759.8K
#407
STELARA(J3358)* J3358
$742.1K
#408
COAGADEX J7175
$737.4K
#409
KIMYRSA J2406
$713.3K
Total claims — #74 of 824
#69
ORTHOVISC J7324
37,232
#70
YUPELRI J7677
37,078
#71
ACTEMRA(J3262) J3262
36,246
#72
JUBBONTI* Q5136
34,987
#73
ENVARSUS XR J7503
34,358
#74
RECLAST* J3489
34,241
#75
RETACRIT(Q5106) Q5106
33,752
#76
LEVULAN J7308
31,923
#77
FERAHEME(Q0138)* Q0138
31,621
#78
EPOGEN(J0885)* J0885
31,448
#79
PRIVIGEN J1459
30,530
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $779.5K | 30,769 | 34,241 | $25.34 | $22.77 |
| 2025 (Q1-Q4) | $4.16M | 103,151 | 147,102 | $40.34 | $28.29 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$4.21M
Medicare paid
$3.03M
Submitted services
685,519
Denial rate
2.9%
Allowed / service
$6.33
Submitted charges
$110.41M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J3489 is utilized CMS · BY PROVIDER · 2024
Medicare Part B services for this code by the rendering provider's state — 509,798 services across 53 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.
📊 What bills under J3489
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-09-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
41 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J3489 billing FAQ
What is HCPCS code J3489?
J3489 is a HCPCS Level II J-code used to bill Injection, zoledronic acid, 1 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J3489?
One unit of J3489 represents 1 MG. Report the number of units equal to the dose administered divided by 1 MG.
How many units of J3489 should I bill?
Divide the dose administered by the code's unit size (1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J3489?
The Medicare Part B payment limit is $3.361 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $3.294 per unit. Payment limits are revised quarterly.
Which NDCs bill under J3489?
41 NDCs currently map to J3489 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J3489 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.